Savara, Inc. SVRA 深 滬
等待開盤 04-02 09:30:00 美东时间
5.58
+0.120
+2.20%
華盛通- 最 高5.70
- 今 開5.52
- 成交量 120.38万股
- 最 低 5.50
- 昨 收 5.46
- 總市值 11.42亿
- 52周最高 7.005
- 市盈率 靜 --
- 換手率 0.59%
- 52周最低 1.89
- 委 比 -90.68%
- 總股本 2.05亿
- 歷史最高 17.187
- 量 比 0.80
- 振 幅 3.66%
- 歷史最低 0.69
- 每 手 1
- 風險率 1.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Savara Receives European Medicines Agency Validation For Submission Of MOLBREEVI MAA In Autoimmune Pulmonary Alveolar Proteinosis
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the EMA has validated the submission of the MOLBREEVI MAA in autoimmune PAP;
03-30 20:16
新浪财经ESG：Savara Inc MSCI（明晟）ESG评级调降至BB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:29
Savara GAAP EPS of -$0.13
Savara press release (SVRA): Q4 GAAP EPS of -$0.13. Research and development expenses for the fourth quarter of 2025 and 2024 were $20.9 million and $23.3 million, respectively. General and administra...
03-14 03:28
Savara Inc. to Relocate Headquarters to Yardley, Pa
Savara Inc. to Relocate Headquarters to Yardley, Pa Savara Inc. said it plans to relocate its headquarters to a new leased office at 19 W. College Avenue, Suite 200, Yardley, Pennsylvania. The company entered into the lease on March 10, 2026, for about 10,795 square feet, with the term set to run fr
03-13 20:33
Savara Q4 EPS $(0.13), Inline
Savara (NASDAQ:SVRA) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
03-13 20:20
Savara Q4 net loss widens as expenses rise
Savara Q4 net loss widens as expenses rise Overview US rare disease drug developer's Q4 net loss widened yr/yr as expenses rose General and administrative expenses increased due to workforce expansion and commercial planning Company achieved key regulatory milestones for MOLBREEVI in US and Europe O
03-13 20:15
BRIEF-Savara Q4 Net Income USD -32.236 Million
BRIEF-Savara Q4 Net Income USD -32.236 Million Mar 13 (Reuters) - Savara Q4 operating expenses USD 33.419 million. Q4 income from operations USD -33.419 million Q4 EPS USD -0.13
03-13 20:05
Savara Says U.S. FDA Will Not Hold Advisory Panel For MOLBREEVI BLA As Review Continues Toward August 22 PDUFA Date; Has Submitted The MAA To The EMA; Submission Of The MAA To The UK Medicines And MHRA Remains On Track By The End Of Q1 2026
-- Day 74 Letter Received from the U.S. Food and Drug Administration (FDA) Indicated the Agency Has No Plans to Convene an Advisory Committee ---- Company has Submitted the Marketing Authorization Application (MAA) to
03-07 05:08
FDA to review Savara resubmitted Molbreevi BLA
The U.S. FDA will review Savara's (SVRA) resubmitted BLA for Molbreevi (molgramostim inhalation solution) to treat the rare lung disease autoimmune pulmonary alveolar proteinosis. The agency granted p...
02-21 05:42
Savara Announces FDA Files For Review Of Biologics License Application For MOLBREEVI As Autoimmune Pulmonary Alveolar Proteinosis Treatment; Sets Aug. 22 As Prescription Drug User Fee Act Target Action Date
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced the FDA has filed for review the BLA for MOLBREEVI as a therapy to treat patients with
02-21 05:17
